Brokers Set Expectations for RAPP Q2 Earnings

Key Points

• HC Wainwright predicts Rapport Therapeutics will report a Q2 2025 EPS of ($0.71), maintaining a "Buy" rating with a target price of $31.00.
• Rapport Therapeutics reported a Q2 loss of ($0.75) EPS, beating the expected consensus estimate of ($0.87).
• Shares of Rapport Therapeutics have increased by 5.5% recently, with a current trading price of $15.41.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings estimates for shares of Rapport Therapeutics in a report issued on Wednesday, August 6th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.71) per share for the quarter. HC Wainwright has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Rapport Therapeutics' current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics' Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($3.14) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($4.44) EPS and FY2029 earnings at ($4.07) EPS.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.12.

Separately, JMP Securities restated a "market outperform" rating and issued a $28.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday, July 8th.

Rapport Therapeutics Trading Up 9.7%

Shares of NASDAQ RAPP traded up $1.39 during mid-day trading on Friday, reaching $15.67. The company had a trading volume of 153,660 shares, compared to its average volume of 189,278. The firm has a 50 day simple moving average of $13.31 and a two-hundred day simple moving average of $11.94. The stock has a market cap of $571.77 million, a P/E ratio of -6.26 and a beta of 0.62. Rapport Therapeutics has a 52-week low of $6.43 and a 52-week high of $29.74.

Insiders Place Their Bets

In other Rapport Therapeutics news, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $14.00, for a total value of $119,000.00. Following the sale, the insider owned 435,142 shares of the company's stock, valued at approximately $6,091,988. The trade was a 1.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.57% of the company's stock.

Institutional Trading of Rapport Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RAPP. TRV GP V LLC purchased a new stake in Rapport Therapeutics during the fourth quarter worth about $126,579,000. TRV GP VI LLC purchased a new stake in Rapport Therapeutics during the fourth quarter worth about $17,194,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new stake in Rapport Therapeutics during the first quarter worth about $2,039,000. Price T Rowe Associates Inc. MD boosted its holdings in Rapport Therapeutics by 9.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company's stock worth $20,285,000 after buying an additional 95,976 shares in the last quarter. Finally, Norges Bank purchased a new stake in Rapport Therapeutics during the fourth quarter worth about $860,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.